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Abstract
Background: Implantation of drug eluting stents (DES) has become a standard treatment of 
patients undergoing percutaneous coronary intervention (PCI). Incomplete strut coverage is 
a potential risk factor for late stent thrombosis. Optical coherence tomography (OCT) enables 
in vivo identification of incomplete neointimal coverage. 
Methods: Study included 62 patients after sirolimus eluting stents (SES) or paclitaxel elut-
ing stents (PES) implantation. OCT examination was performed at least 24 months after the 
initial procedure (35.4± 9.4 months). In cross-sectional still frames selected from each 1 mm of 
analyzed stents a total number of visible struts and number of struts with or without complete 
neointimal coverage was assessed. Measurements of neointimal coverage, presented as a mean 
thickness of tissue, were performed. Patients were followed up for 3 years and the frequency of 
major adverse cardiac events was recorded. 
Results. In the analyzed 28 SES and 37 PES 9998 struts were identified. Complete neointimal 
coverage was observed in 83.5% and 79.2% of SES and PES struts respectively (p = 0.48). 
There was no difference in incidence of not covered or malapposed struts between SES and 
PES groups. Mean thickness of the tissue covering SES struts was 0.165 ± 0.095 mm, and 
0.157 ± 0.121 mm for PES. The mean neointimal thickness difference (SES vs. PES) was not 
statistically significant. In a 36 months follow-up 1 death was observed — potentially attributed 
to stent thrombosis. 
Conclusions: A long term OCT follow-up after DES implantation shows high incidence of 
uncovered struts regardless of the stent type. Clinical significance of this finding remains que-
stionable and requires further large scale trials. (Cardiol J 2013; 20, 3: 247–253)
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Introduction
Implantation of drug eluting stents (DES) 
has become a  standard method of treatment of 
patients with stable coronary artery disease (CAD) 
undergoing percutaneous coronary interventions 
(PCI). Although DES reduced rates of restenosis 
compared with bare metal stents (BMS), late 
thrombosis, a  life-threatening complication has 
emerged as a major concern. Incomplete strut 
coverage observed in follow-up period has been 
currently identified as a potential risk factor leading 
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to the occurrence of late stent thrombosis (LST) 
[1, 2]. In pathology studies incomplete neointimal 
coverage of stent struts was identified as powerful 
surrogate indicator of endothelialization and the 
most important morphometric predictor of LST [3].
Optical coherence tomography (OCT) is 
a novel diagnostic method that enables in vivo 
identification of incomplete coverage after stent 
implantation [4–6]. High OCT resolution allows 
for accurate evaluation of both the PCI effect and 
the vessel wall response to damage caused by the 
implanted stent. Additionally this method provi-
des precise assessment of stent expansion and its 
apposition [7, 8].
Currently there is a  limited number of pub-
lished data regarding the comparison of struts 
coverage in paclitaxel (PES) and sirolimus (SES) 
eluting stents in a long term perspective. Hence, 
the purpose of present study was to assess the 
pattern of strut coverage in different types of DES 
in long term follow-up using OCT. Moreover, we 
sought to examine the relationship between strut 
coverage and clinical outcome.
Methods
The studied population comprised of patients 
with stable CAD who underwent PCI with im-
plantation of PES (Taxus, Boston Scientific) or 
SES (Cyper, Cordis) between January 2003 and 
December 2005. Single-centre registry included 
234 consecutive patients, 62 of them met the inclu-
sion criteria and were involved in the study (Fig. 1).
The inclusion criteria were as follows:
—  DES implantation in clinically and angiogra-
phically significant lesion of native vessel;
—  At least 24 month since index PCI procedure;
—  Stent diameter 2.5–3.5 mm.
 Exclusion criteria:
—  History of target vessel revascularization 
(TVR), myocardial infarction (MI) and stroke 
in a period between index PCI and planned 
OCT examination;
—  Lack of capability to perform OCT measu-
rement with proximal balloon occlusion (left 
main, proximal lesion [< 10 mm from native 
vessel ostium]);
—  Implantation of DES in a chronic total occlu-
sion of native artery;
—  Chronic kidney disease with baseline GFR < 
< 30 mL/min/1.73 m2;
After OCT examination patients were prospec-
tively followed-up for the period of 3 years. Frequ-
ency of major adverse events defined as all-cause 
mortality, MI, stroke and repeat revascularization 
was registered.
The study was approved by the local research 
ethics committee and was conducted in accordance 
with Declaration of Helsinki.
OCT data collection and analysis
The OCT evaluation was performed in all 
patients included in the study using the M2 Car-
diology Imaging System (LightLab Imagining Inc.) 
in accordance with manufacturer examination 
protocol. Low pressure occlusive over-the-wire 
balloon (Helios) was placed in the target vessel 
proximally to the lesion. An optic fibre probe 
(ImageWire, LightLab Imaging Inc.) was inserted 
through the balloon to the distal part of the vessel. 
After proximal balloon occlusion an automatic OCT 
pullback was performed at the speed of 2 mm/s 
with a continuous Ringer lactate solution infusion. 
The image analysis was performed based on 
the consensus of 2 experienced observers, blinded 
to the patients’ clinical characteristics. Cross-
-sectional still frames were selected from each 
1 mm of analyzed segment. Frames with major 
visual artefacts that prevented reliable assessment 
Number of patients who
met inclusion criteria
n = 62 (26.5%)
Number of patients who
met exclusion criteria
n = 60 (25.6%)
Number of patients who
refused to participate
n = 46 (19.7%)
Number of patients with
target vessel
revascularization
n = 27 (11.5%)
Number of patients died
n = 7 (3.0%)
Number of patients lost
to follow−up
n = 32 (13.7%)
Total number of patients with DES
implanted between January 2003
and December 2005
n = 234 (100%)
Figure 1. Patients enrollment flow chart; DES — drug 
eluting stents.
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of stent struts were excluded. In all remaining 
cross-sections the lumen and stent cross sectional 
area as well as the total number of visible struts 
and number of struts with and without coverage, 
were assessed. The measurements of the strut 
coverage, presented as a mean thickness of tis-
sue, were performed on every visible stent strut 
(2 measurements per strut). Based on the OCT 
analysis 2 following stent strut coverage types 
were recognized: strut covered with homogenous 
layer of tissue (covered strut — Fig. 2) and strut 
without complete tissue coverage (uncovered strut 
— Fig. 3). Struts were considered to be “covered” 
if a layer of tissue was clearly visible on the strut 
surface. The OCT ”uncovered” struts were identi-
fied when no evidence of tissue was visualized over 
the struts or if the strut was covered only partially. 
Additionally cases of stent malapposition were 
identified. Malapposition was defined as a separa-
tion of the stent struts from the intimal surface of 
the arterial wall at a distance greater than the strut 
thickness including the polymer. Taking into con-
sideration spatial resolution of the OCT (20 µm), 
the malapposition was recognized when the strut 
distance from the vessel wall was greater than 
160 µm and 150 µm for SES and PES, respectively. 
Statistical analysis
The quantitative variables were presented 
as the mean values ± standard deviation (SD). 
For categorical variables the relative and absolute 
frequencies are shown. The t-Student and Fischer 
tests were performed for subgroup comparisons. If 
the distribution was skewed a non-parametric test 
was used. A p value less than 0.05 was considered 
statistically significant. All analyses were perfor-
med using SAS software.  
Results
The study population comprised of 62 patients 
with stable CAD who underwent PCI with DES 
implantation in de novo lesions. There were 45 
(72.6%) male, the mean age was 60.9 ± 9.8 year. 
In total there were 65 stents analyzed (28 SES and 
37 PES). One patient in the SES group and 2 in the 
PES group received 2 stents in the target lesion. 
The mean follow-up time between the PCI and the 
OCT assessment was 35.4 ± 9.4 months. 
Clinical characteristics and baseline angio-
graphic data of the prespecified subgroups are 
presented in Tables 1 and 2. There were no sig-
nificant differences with regard to the risk factors 
of the cardiovascular disease and the angiographic 
profiles. The latter included target vessel, length 
and diameter of the stent, time from PCI to OCT 
assessment. 
OCT analysis
In total, 1624 cross sections were obtained and 
1552 (95.6%) were included in the final analysis. 
There were 9998 struts identified, 4442 in the 
Figure 2. Strut with homogenous layer of tissue (co­
vered).
Figure 3. Strut without complete tissue coverage (un­
covered). 
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Table 1. Clinical characteristics of the study group.
SES (n = 27 patients) PES (n = 35 patients)
Age [years] 60.3 62.4
Gender (male) 16 (59.3%) 29 (82.9%)
Previous myocardial infarction 8 (29.6%) 10 (28.6%)
Hypertension 14 (51.9%) 21 (60%)
Hyperlipidemia 16 (59.3%) 29 (82.9%)
Diabetes mellitus 7 (25.9%) 11 (31.4%)
Obesity 6 (22.2%) 7 (20%)
Smoker 4 (14.8%) 5 (14.3%)
Chronic kidney disease 3 (11.1%) 3 (8.6%)
Left ventricle ejection fraction [%] 52 ± 6 55 ± 7
Mean follow­up time 37.2 ± 11.7 34.1 ± 5.7
SES — sirolimus eluting stent; PES — paclitaxel eluting stent
Table 2. Baseline angiographic characteristics of the prespecified subgroups.
SES (n = 28 stents) PES (n = 37 stents) P
Target vessel
Left anterior descending artery 16 (57.2%) 20 (54%) NS
Circumflex artery 6 (21.4%) 8 (21.6%) NS
Right coronary artery 6 (21.4%) 9 (24.4%) NS
Lesion type: NS
A 4 (14.3%) 0 (0%)
B1 4 (14.3%) 6 (16.2%)
B2 9 (32.1%) 12 (32.4%)
C 11 (39.3%) 20 (54.1%)
Mean stent diameter [mm] 3.01 ± 0.25 3.12 ± 0.38 NS
Mean stent length [mm] 24.64 ± 6.8 24.62 ± 5.8 NS
Direct stenting 3 (10.7%) 4 (10.8%) NS
Post­dilatation 23 (82.1%) 31 (83.8%) NS
Maximum inflation pressure 16.8 ± 2.6 16.2 ± 3.5 NS
SES — sirolimus eluting stent; PES — paclitaxel eluting stent
Table 3. Analysis of the optical coherence tomography (OCT) findings.
SES PES P
Total number of cross sections 684 940 –
Number of cross sections included in the analysis 648 904 –
Number of analyzed struts 4442 5556 –
Number of covered struts 3711 (83.5%) 4402 (79.2%) 0.48
Number of uncovered struts 731 (16.5%) 1154 (20.8%) 0.43
Mean tissue thickness covering the strut [mm] 0.160 ± 0.095 0.157 ± 0.121 0.59
Number of malapposed struts 87 (1.9%) 145 (2.6%) 0.68
Frequency of malapposition (%) 45 (6.9%) 56 (6.2%) 0.62
Frequency of cross sections with the ratio  
of covered struts/total struts > 30%
149 (23.0%) 273 (30.2%) 0.57
Neointimal hyperplasia area measured by OCT [mm2] 1.46 ± 0.87 1.59 ± 1.34 0.64
SES — sirolimus eluting stent; PES — paclitaxel eluting stent
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SES group and 5556 in the PES group. Complete 
coverage was observed in 83.5% struts of the SES 
group and 79.2% of the PES group. The mean 
tissue thickness over the strut was 0.160 ± 0.095 
mm and 0.157 ± 0.121 mm in the SES and PES 
groups, respectively. In the SES group 2% and in 
the PES group 2.6% of struts met the malapposition 
criterion as defined above. There were 6.9% and 
6.2% of cross sections showing malapposition in 
the SES and PES groups, respectively. Additionally 
we analyzed the number of cross sections with ratio 
of uncovered struts to total number of struts above 
0.3. There were no significant differences between 
the groups in terms of the OCT findings (Table 3).
The percentage of struts covered with the 
neointimal tissue of a thickness less than 150 µm, 
below intravascular ultrasound (IVUS) spatial 
resolution, was identified in 56.7% of the SES 
group and 61.8% of the PES group. The frequency 
distribution of neointimal thickness on stent struts 
is summarized in Figure 4.
Clinical follow-up
During the 36 months follow-up clinical data 
from 58 (93.5%) patients was collected. There were 
4 deaths (2 in SES group and 2 in PES group): 2 due 
to cancer, 1 due to stroke, 1 due to unknown reason 
(probable stent thrombosis according to ARC defi-
nition); 1 non-fatal MI of the non-culprit artery in 
the PES group; 1 patient required revascularization 
due to restenosis of the culprit vessel (SES group).
Discussion
The OCT a novel diagnostic method for the 
coronary artery imaging, introduced recently in 
to clinical practice, provides a new approach to 
a long term follow-up of patients after PCI proce-
dures. Due to high spatial resolution OCT offers 
precise measurement of the neointimal thickness 
and distribution [9]. Additionally OCT enables 
assessment of tissue coverage of the each stent 
strut [10, 11]. The struts are considered to be 
“OCT covered” if a  layer of the tissue is clearly 
visible on surface of the struts. On the contrary, 
the “OCT uncovered” struts are recognized when 
no evidence of tissue could be visualized above 
the struts [12]. Stent apposition is another para-
meter which can be precisely assessed by OCT. 
The malappostion, defined as a separation of the 
stent struts from the intimal surface of the arterial 
wall at a distance greater than the strut thickness 
including the polymer, is caused mainly by positive 
remodeling and the absorption of the thrombus 
located between the stent and the vessel wall [13, 
14]. This definition mainly depends on the strut 
thickness and may lead to ambiguity in the recog-
nition of malapposition between different types of 
stents. The malapposition is often associated with 
uncovered struts and presence of the thrombus 
— the potential risk factors for the LST [15, 16]. 
Although clinical implication of OCT derived stent 
assessment remains unknown, both neointimal 
coverage and the occurrence of malapposition seem 
to be important risk factors of stent thrombosis 
[17]. The issue of DES coverage was addressed in 
autopsy study published by Finn et al. [3]. In the 
multivariate analysis they identified the degree 
of the stent coverage as the significant predictor 
of LST in DES patients. The presence of 30% of 
uncovered struts per cross section accounted for 
nine fold increase in the risk of in-stent thrombus 
formation (odds ratio = 9.0; 95% CI 3.5–22). Addi-
tionally, in cases with thrombus present, a greater 
prevalence of incomplete strut apposition was 
found when compared to those without thrombus 
(29% vs. 6%; p = 0.02).
In our study we assessed the degree of strut 
coverage in DES in a long term follow-up using the 
OCT. In the studied population the high frequency 
of uncovered struts were observed, regardless of 
stent type. Late malapposition was a  relatively 
rare phenomenon, equally distributed in both 
subgroups. Likewise, there were no differences 
in terms of number of uncovered struts and the 
neointimal thickness. The percentage of struts 
covered by the layer of tissue greater than 150 µm 
Figure 4. The frequency distribution of neointimal thick­
ness on stent struts.
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were 56.7% and 61.8% in SES and PES group, re-
spectively. This finding suggests that in majority 
of cases the IVUS, with its spatial resolution of 
more than 150 µm, might not be an adequate tool 
to assess the neointimal strut coverage.
In the study performed by Matsumoto et al. 
[18], 34 patients with total number of 57 sirolimus 
stents were assessed by both IVUS and OCT [18]. 
At 6 months only 16% of stents were identified to 
have all the struts fully covered with a visible layer 
of tissue. In the remaining 84% of stents, struts with 
no coverage were visualized by the OCT. Moreover, 
the percentage of struts covered with a layer of tissue 
undetectable by IVUS reached 64%. 
Healing pattern in different types of stents 
was also assessed by Chen et al. [19]. They com-
pared the neointimal stent coverage in a group of 
24 patients after SES and BMS implantation [19]. 
In the BMS patients in whom the OCT follow-
up was completed between 5 to 10 months post 
stent implantation, OCT revealed the minimal 
and maximal neointimal thickness of 0.2 and 
0.59 mm, respectively. In the subgroup of patients 
at 23 to 93 months after BMS implantation these 
2 parame ters were comparable. This finding may 
suggest that the healing process is completed 
within first months post BMS implantation. In the 
SES group at the 6 to 12 months follow-up the 
minimal and maximal neointimal thickness was 
significantly smaller when compared to the BMS 
group (0.04 mm and 0.12 mm). In the BMS group 
99.7% of struts were covered with tissue compared 
to 83% in the SES group. Moreover, malapposition 
defined as separation of the strut from the internal 
layer of the vessel wall of more than 200 µm, was 
significantly more frequent in SES group and ac-
counted for 2% of cases.
Similar results were reported in the acute 
coronary syndrome (ACS) patients from the OCT 
substudy of HORIZONS AMI (Harmonizing Outco-
mes With Revascularization and Stents in Acute 
Myocardial Infarction) trial [20]. This study com-
pared the safety and efficacy of primary angioplas-
ty with PES or BMS implantation in patients with 
ST segment elevation MI. The OCT measurement 
was performed 13 months after PCI. In total 
155 PES and 44 BMS were analyzed, which 
corresponded to over 40 thousand struts. In 
the BMS group 0.93% of struts were uncovered 
when compared to 4.79% in the PES group. The 
occurrence of strut malapposition was signifi-
cantly higher in the PES group than in the BMS 
group (1.21% vs. 0.12%). In our study we found 
a  relatively high incidence of uncovered struts 
despite of the long period from the implantation. 
Comparable results were reported by Kim et al. 
[21] who studied the ACS population treated with 
SES implantation. They also noticed significant 
difference in SES strut coverage between the 
ACS group and the stable CAD (17.3% vs. 4.4%; 
p < 0.05, respectively). 
Limitations of the study
There are few limitations of our study that 
should be emphasized. First of all, this is a retro-
spective analysis of single-centre registry that 
included a  limited number of patients after DES 
implantation. It is worth noticing that despite of 
relatively large number of struts included in the 
analysis, the limited number of stents, small size 
of the study population, retrospective character 
of the study and potential selection bias, do not 
allow for conclusive interpretation of the results. 
Further studies are needed to confirm the obtained 
outcomes. 
Another constrain of our study derives from 
the limitation directly related to the OCT techni-
que. The OCT resolution threshold does not allow 
for definite assessment of neointimal layer thinner 
than 20 µm. There is limited published data regar-
ding direct comparison of the OCT images with 
the pathological findings. In the study by Prati et 
al. [22] 8 stents implanted in to the rabbit carotid 
artery was evaluated using the OCT technique. 
As reference method microscopic examination of 
the histopathology samples of the neointima was 
performed. OCT allowed proper identification of 
97.4% struts visible in pathological cross sections. 
In all examined cases OCT was as precise as 
microscopy in identification of both covered and 
uncovered struts. The degree of neointimal cove-
rage correlated with the time from angioplasty and 
was equal to 0%, 12%, 41% and 97% in 2nd, 7th, 15th 
and 28th day of post PCI, respectively (p < 0.001). 
Furthermore, there were no differences in term of 
the tissue thickness over the strut as well as the 
mean cross-sectional area of the stent, as asses-
sed by the corresponding methods. The minimal 
neointimal thickness measured in the pathological 
examination was 0.025 mm and was similar to the 
result obtained in the OCT (0.024 mm). 
Results of the presented studies suggest that 
OCT may become a reliable reference method for 
long term evaluation of neointimal strut coverage 
and the PCI outcomes after stent implantation. 
However, stent endothelialization is a dynamic 
process and significant changes in tissue type and 
degree of strut coverage occur in a period of time. 
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During the first months there is large proportion of fi-
brin in the newly formed tissue that cannot be reliably 
distinguished from the neointima in the OCT imaging. 
Hence, those struts that present with a tissue layer 
visualized in the OCT should be rather described as 
“OCT-covered”, the term not equal to the real degree 
of the stent endothelialization. 
Conclusions
The long term follow-up of stable coronary 
artery patients with complex coronary lesions 
treated with SES or PES angioplasty revealed 
a high occurrence of uncovered struts in the OCT 
examination. There were no significant differences 
in terms of degree of strut coverage and incidence 
of malapposition between the study groups. The 
constrains of the OCT and the lack of pathologic 
reference studies cast doubt on the clinical utility 
of the “OCT uncovered struts” as a potential surro-
gate endpoint of incomplete endothelialization and 
the healing process after stent implantation. The 
clinical implication of the OCT findings of the strut 
coverage requires verification in further studies. 
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